U.S. Senate committee chair: Mylan's response on EpiPen price hike 'incomplete'
- S&P, Dow rise on health stocks; Nasdaq weighed by Comcast
- Unusual 11 Mid-Day Movers 10/27: (PCMI) (OCN) (TTMI) Higher; (CYH) (RWLK) (AMFW) Lower
- Twitter (TWTR) Tops Q3 EPS by 4c; Announces Restructuring, Workforce Reduction
- Qualcomm (QCOM) to Acquire NXP Semi (NXPI) in $47B Deal
- Tesla (TSLA) Posts Q3 adj.-EPS of 71c
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
WASHINGTON (Reuters) - The chairman of the U.S. Senate Judiciary Committee probing Mylan NV's EpiPen price hike on Friday said its response to his query was "incomplete," and called on the drugmaker to give more details over how much government health insurance programs pay for the allergy treatment.
"It's an incomplete response and wouldn't satisfy my constituents who are upset about the EpiPen price increases. It doesn't provide the full picture that I requested, and it doesn't answer all of my questions," U.S. Senator Chuck Grassley said in a statement. He added that it is still unclear how many patients will benefit from Mylan's expanded assistance programme.
(Reporting by Susan Heavey, editing by G Crosse)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan Launches First Generics of Benicar® and Benicar HCT® Tablets
- Tesla up on surprise profit, reassurance on capital plans
- As cracks emerge in global oil pact, Saudis may need to compromise
Create E-mail Alert Related CategoriesGeneral News, Litigation, Reuters
Related EntitiesRaising Prices
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!